Paul W. Graves
Known title: DirectorCIK: 0001559551
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
CRL Analyst Targets Rise After UBS Reinstates Coverage. Charles River Laboratories saw its average analyst price target increase to $305.00, driven by UBS reinstating coverage with a $357.00 target. This move follows reports of stabilizing demand and increased interest in animal model markets. The stock is currently trading below its 52-week high, with technical indicators showing support near $181.76.
Transaction History
| AU | ▲ Buy | Grant | 967 | $0 | 10/1/2026 | View on chart |
| CRL | ▲ Buy | Grant | 1,438 | $255K | 5/8/2026 | View on chart |
| CRL | ▲ Buy | Grant | 946 | $128K | 6/2/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Goldman Sachs Initiates Coverage of AngloGold Ashanti with $104 Target
Goldman Sachs began coverage of AngloGold Ashanti, assigning a $104 price target and noting the company's growth and cash‑flow outlook among top African gold miners. The firm’s initiation appears alongside a broader analyst call list that includes AngloGold. Recent trading shows the shares falling more than the market, hovering near the $93.08 support level. The average analyst target remains higher at $117.50.
Goldman Sachs Initiates Coverage of AngloGold Ashanti with $104 Target. Goldman Sachs began coverage of AngloGold Ashanti, assigning a $104 price target and noting the company's growth and cash‑flow outlook among top African gold miners. The firm’s initiation appears alongside a broader analyst call list that includes AngloGold. Recent trading shows the shares falling more than the market, hovering near the $93.08 support level. The average analyst target remains higher at $117.50.